Clinical trials: IBS - Irritable Bowel Syndrome
Irritable Bowel Syndrome
Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)
Irritable bowel syndrome (IBS) affects about 15% of the U.S. population. There are still no effective and safe medications approved for the treatment of abdominal pain associated with bowel symptoms in IBS.
- Trial name
- NCT01253408
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome With Constipation (IBS-C)
A Study of the Effect of SYN-010 on Subjects With IBS-C
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared with Placebo on Breath Methane Production in Breath Methane-Positive Subjects with…
- Trial name
- NCT02495623
- Testing
- SYN-010 21 mg, SYN-010 42 mg
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Theriva Biologics, Inc.
Irritable Bowel Syndrome With Constipation
Effect of Tai Chi as Treatment for IBS-C
The purpose of the study is to evaluate the efficacy of Tai Chi practice in reducing symptoms of Irritable Bowel Syndrome with Constipation (IBS-C).
- Trial name
- NCT04132804
- Testing
- Tai Chi
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Massachusetts General Hospital
Functional Abdominal Pain, Functional Dyspepsia
Efficacy of Open Label Placebo in Children With FGIDs
This study is aimed at investigating the efficacy of placebo for symptom relief in children with abdominal pain related functional gastrointestinal disorders.
- Conditions
- Functional Abdominal Pain, Functional Dyspepsia, Irritable Bowel Syndrome, Functional Gastrointestinal Disorders
- Trial name
- Placebo (NCT02389998)
- Testing
- Hyoscyamine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Boston Children's Hospital
Irritable Bowel Syndrome
Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome
This study will evaluate the efficacy and safety of vibegron, a beta-3 adrenergic receptor (β3-AR) agonist, in the treatment of pain associated with irritable bowel syndrome (IBS) due to IBS with predominant diarrhea (IBS-D) or…
- Trial name
- NCT03806127
- Testing
- Vibegron
- Where
- 41 sites in United States
- Volunteers
- 222 people
- Sponsor
- Urovant Sciences GmbH
Irritable Bowel Syndrome (IBS), Functional Abdominal Pain
Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents
This protocol matches child subjects with peer mentors of similar age who have learned to function successfully with a chronic pain disorder.
- Conditions
- Irritable Bowel Syndrome (IBS), Functional Abdominal Pain, Fibromyalgia, Complex Regional Pain Syndrome (CRPS)
- Trial name
- NCT01118988
- Testing
- Mentorship
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Los Angeles
Irritable Bowel Syndrome With Constipation
Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
The purpose of this study is to determine the safety and efficacy of linaclotide administered to patients with Irritable Bowel Syndrome with Constipation (IBS-C).
- Trial name
- NCT00938717
- Where
- 107 sites in United States
- Volunteers
- 805 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome
Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)
Purpose: The investigators are proposing to examine the use of Savella® (Milnacipran) for treating irritable bowel syndrome (IBS) in women. Participants: Eligible participants will meet the Rome III diagnostic criteria for IBS.
- Trial name
- NCT01471379
- Testing
- Milnacipran
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Spencer Dorn, MD, MPH
Irritable Bowel Syndrome (IBS)
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
This is a double-blind, placebo-controlled, randomised crossover study to investigate the efficacy and safety of GW876008
- Trial name
- NCT00421707
- Testing
- GW876008
- Where
- 23 sites in United States, Canada
- Volunteers
- 133 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome With Diarrhea
Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use
This study will evaluate the efficacy and safety of eluxadoline 100 milligrams (mg) twice a day (BID) versus placebo for the treatment of patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) who report that the use of…
- Trial name
- NCT02959983
- Testing
- Eluxadoline
- Where
- 83 sites in United States, Canada
- Volunteers
- 346 people
- Sponsor
- Allergan
Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea
Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption
To compare with a randomized trial (n=15 per treatment group), effects of colesevelam and placebo treatment, on colonic transit, bowel functions, permeability and tight junction expression in rectosigmoid mucosa of IBS-D with…
- Conditions
- Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption
- Trial name
- NCT03270085
- Testing
- Colesevelam
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome
Dietary Triggers of Gastrointestinal Symptoms in IBS Patients
This crossover randomized controlled trial will evaluate the effects of purified gluten and whole wheat (gluten combined with amylase-trypsin inhibitors (ATIs)) on inducing intestinal and extra-intestinal symptoms in irritable…
- Trial name
- NCT03664531
- Testing
- Purified gluten, Non-purified gluten (containing ATIs)
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- McMaster University
Constipation-predominant Irritable Bowel Syndrome
Cheno Effect on Transit in Health and IBS-C
The study hypothesis is that the naturally occurring bile acid, chenodeoxycholic acid, induces acceleration of colonic transit in health and in patients with constipation-predominant Irritable Bowel Syndrome (IBS-C).
- Trial name
- Chenotransit (NCT00912301)
- Testing
- Sodium chenodeoxycholate (NaCDC)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Constipation Predominant Irritable Bowel Syndrome
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
This phase 3, 26-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of one dose of Tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as…
- Trial name
- T3MPO-2 (NCT02686138)
- Testing
- Tenapanor
- Where
- 117 sites in United States
- Volunteers
- 593 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome With Diarrhea
Eluxadoline Bile Acid Malabsorption (BAM) Study
This study will evaluate the possibility of a differential effect of eluxadoline on altered bowel function in Irritable Bowel Syndrome with Diarrhea (IBS-D) participants with and without evidence of Bile Acid Malabsorption (BAM).
- Trial name
- NCT03441581
- Testing
- Eluxadoline
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Allergan
Irritable Bowel Syndrome
Self Administered Cognitive Behavior Therapy for Irritable Bowel Syndrome
The primary goal of the proposed trial is to assess the short- and long-term efficacy of cognitive behavior therapy (CBT) for irritable bowel syndrome using two treatment delivery systems (self administered, therapist…
- Trial name
- NCT00738920
- Testing
- Self Administered Cognitive Behavior Therapy, Therapist Administered Cognitive Behavior Therapy, Behavioral Education and Supportive Therapy
- Where
- 2 sites in United States
- Volunteers
- 436 people
- Sponsor
- State University of New York at Buffalo
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553591
- Testing
- Eluxadoline
- Where
- 283 sites in United States, Canada and 1 more
- Volunteers
- 1,282 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Functional Constipation, Irritable Bowel Syndrome With Constipation
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
The objective of LIN-MD-64 is to evaluate the safety and efficacy of 12 weeks of linaclotide therapy (72 μg daily) in comparison with placebo in pediatric participants, 6 to 17 years of age, who fulfill modified Rome III Criteria…
- Trial name
- NCT04026113
- Testing
- Linaclotide
- Where
- 115 sites in United States, Belgium and 12 more
- Volunteers
- 438 people
- Sponsor
- AbbVie
Irritable Bowel Syndrome With Diarrhea
Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea.
- Trial name
- IRIS-2 (NCT01303224)
- Testing
- Ibodutant
- Where
- 71 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 565 people
- Sponsor
- Menarini Group
Gastrointestinal Diseases
Gastrointestinal Myoelectric Activity Protocol, the G-Tech EEnG Protocol
A feasibility study for monitoring and recording gastrointestinal (GI) myoelectric activity in subjects with suspected or diagnosed irritable bowel syndrome (IBS) and reports of GI pain and asymptomatic subjects without IBS and…
- Trial name
- NCT01697397
- Testing
- Recording of Myoelectric Signals
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- G-Tech Corporation